Immunovant Future Growth

Future criteria checks 2/6

Immunovant is forecast to grow earnings and revenue by 35.3% and 74.7% per annum respectively. EPS is expected to grow by 35.6% per annum. Return on equity is forecast to be -248.6% in 3 years.

Key information

35.3%

Earnings growth rate

35.61%

EPS growth rate

Biotechs earnings growth	23.9%
Revenue growth rate	74.7%
Future return on equity	-248.62%
Analyst coverage	Good
Last updated	15 Dec 2025

Recent future growth updates

Recent updates

Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 97% Above Its Share Price

Feb 06

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 27

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

Earnings and Revenue Growth Forecasts

NasdaqGS:IMVT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2028	88	-557	-522	-595	10
3/31/2027	17	-562	-497	-552	10
3/31/2026	N/A	-518	-440	-444	11
9/30/2025	N/A	-465	-431	-431	N/A
6/30/2025	N/A	-447	-418	-417	N/A
3/31/2025	N/A	-414	-377	-376	N/A
12/31/2024	N/A	-383	-326	-325	N/A
9/30/2024	N/A	-323	-272	-272	N/A
6/30/2024	N/A	-273	-244	-243	N/A
3/31/2024	N/A	-259	-215	-214	N/A
12/31/2023	N/A	-243	-211	-210	N/A
9/30/2023	N/A	-255	-210	-210	N/A
6/30/2023	N/A	-245	-170	-170	N/A
3/31/2023	N/A	-211	-188	-188	N/A
12/31/2022	N/A	-199	-166	-165	N/A
9/30/2022	N/A	-177	-151	-151	N/A
6/30/2022	N/A	-167	-151	-151	N/A
3/31/2022	N/A	-157	-106	-106	N/A
12/31/2021	N/A	-138	-96	-96	N/A
9/30/2021	N/A	-128	-87	-87	N/A
6/30/2021	N/A	-111	-91	-91	N/A
3/31/2021	N/A	-107	-84	-83	N/A
12/31/2020	N/A	-100	-84	-84	N/A
9/30/2020	N/A	-79	-66	-65	N/A
6/30/2020	N/A	-73	-59	-59	N/A
3/31/2020	N/A	-66	-53	-53	N/A
12/31/2019	N/A	-55	-43	-43	N/A
9/30/2019	N/A	-52	-46	-46	N/A
6/30/2019	N/A	-44	N/A	-32	N/A
3/31/2019	N/A	-29	N/A	-29	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMVT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMVT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMVT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMVT's revenue (74.7% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: IMVT's revenue (74.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IMVT is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/24 22:38
End of Day Share Price	2025/12/24 00:00
Earnings	2025/09/30
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Cantor Fitzgerald & Co.

Immunovant Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 7.9% to US$41.57

Consensus EPS estimates fall by 17%

Price target increased by 17% to US$34.42

Price target increased by 14% to US$28.23

Price target increased by 11% to US$20.25

Price target increased to US$13.00

Recent updates

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Immunovant, Inc. has completed a Follow-on Equity Offering in the amount of $550.2 million.

Chief Medical Officer notifies of intention to sell stock

New minor risk - Insider selling

Chief Operating Officer recently sold US$298k worth of stock

Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025

Immunovant, Inc. to Report Q2, 2026 Results on Nov 10, 2025

Immunovant Unveils Durability and Treatment-Free Six-Month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Price target decreased by 7.9% to US$41.57

Immunovant, Inc., Annual General Meeting, Aug 27, 2025

Immunovant, Inc. Announces CEO Changes

CEO & Director recently sold US$365k worth of stock

Immunovant,Inc. Reports Topline Results from Its Phase 3 Study of Batoclimab in MG and Initial Results from Period 1 of Its Phase 2B Study in CIDP

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Now 27% undervalued after recent price drop

CEO & Director recently sold US$322k worth of stock

Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 97% Above Its Share Price

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it has received $450 million in funding from Roivant Sciences Ltd., FMR LLC, Fidelity Management & Research Company LLC

Immunovant, Inc. announced that it expects to receive $450 million in funding from Roivant Sciences Ltd. and other investors

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Chief Financial Officer recently sold US$52k worth of stock

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

Immunovant, Inc., Annual General Meeting, Aug 17, 2022